{
    "clinical_study": {
        "@rank": "139653", 
        "arm_group": {
            "arm_group_label": "Coenzyme Q10U, L-carnitine", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive combination of  coenzyme Q10U 180 milligram and L-carnitine 2000 milligram"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is determine whether combination Q10 , L-carnitine and\n      multivitamin and mineral complex is effective in treatment of patients with low and\n      intermidiate1-2 risk Myelodysplastic syndrome"
        }, 
        "brief_title": "The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objectives of this study are to assess response (as measured by increase in\n      blood counts, cytogenetic/molecular changes in the bone marrow, improved endurance) to the\n      supplements treatment.\n\n      The secondary objectives are to determine:\n\n      Quality of life assessment(FACT: QOL Questionnaire) Cancer fatigue reduction. Physiological\n      functioning assessment Rate and depth transfusion reduction Duration of response. Time to\n      progression. Overall survival. Estimated cytokine profile and another immunological and\n      biochemical parameters of mitochondrial function before and after six months of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patient willing and able complies with the protocol requirements. Patient given voluntary\n        written informed consent before performance of any study-related procedure that is not\n        part of standard medical care; with the understanding that the consent may be withdrawn by\n        the patient at any time without prejudice to their future medical care.\n\n        Patient is older than 18 years at the time of signing the informed consent. Patients older\n        than 80 years will sign informed consent after psycho-geriatric evaluation.\n\n        Patient diagnosed with Myelodysplastic syndrome, Low risk and intermediate-1risk according\n        to international prognostic scoring system with hemoglobin level less than 11g/l or\n        platelets less than 100000/ mcl or absolute neutrophils count less than 1000/mcl. With or\n        without fatigue syndrome.\n\n        INT-2 and high risk patients may be included into this trial when they are not eligible\n        for other treatment except Best Supportive Cure or failure to other conventional treatment\n        approach.\n\n        Bone marrow aspiration examination including cytogenetics performed up to 12 months before\n        inclusion and absence clinic-laboratory evidence of progressive disease in last month\n        Patient has a life-expectancy > 3 months\n\n        Exclusion Criteria:\n\n        Any serious medical conditions, including the presence of laboratory abnormalities, which\n        places the subject at an unacceptable risk if he or she participates in this study or\n        confounds the experimental ability to interpret data from the study.\n\n        Pregnant or lactating females. Prior history of malignancies, other than MDS, unless the\n        subject has been free of the disease for \u2265 3 years. Exceptions include the following:\n        Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ\n        of the cervix, Carcinoma in situ of the breast, Incidental histological finding of\n        prostate cancer (TNM stage of T1a or T1b).\n\n        Bone marrow blast count >30%. Patient has known active infectious hepatitis B or C, or HIV\n        infection Administration of investigational drugs in the last 3 months. High risk MDS\n        patients and INT-2 patients who are candidates for cytoreductive or epigenetics treatment.\n\n        Any psychological, sociological condutions likely to affect compliance with the study\n        follow-up schedule."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042482", 
            "org_study_id": "KMC01-35-12"
        }, 
        "intervention": {
            "arm_group_label": "Coenzyme Q10U, L-carnitine", 
            "intervention_name": "Coenzyme Q10U, L-carnitine", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carnitine", 
                "Ubiquinone", 
                "Coenzyme Q10"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ultra coenzyme Q10", 
            "L-carnitine"
        ], 
        "lastchanged_date": "January 19, 2014", 
        "location": {
            "contact": {
                "email": "kalmanph@clalit.org.il", 
                "last_name": "Kalman Filanovsky, MD", 
                "phone": "97289441747"
            }, 
            "facility": {
                "address": {
                    "city": "Rehovot", 
                    "country": "Israel", 
                    "zip": "76100"
                }, 
                "name": "Kaplan Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect of the Nutritional Supplements: Ultra Q10 and L-carnitine on the Clinical Course of Myelodysplastic Syndrome", 
        "overall_contact": {
            "email": "kalmanph@clalit.org.il", 
            "last_name": "Kalman Filanovsky, , MD", 
            "phone": "972-89441747"
        }, 
        "overall_contact_backup": {
            "email": "levsh@clalit.org.il", 
            "last_name": "Lev Shvidel, MD", 
            "phone": "97289441383"
        }, 
        "overall_official": {
            "affiliation": "Kaplan Medical Center, Institute of hematology", 
            "last_name": "Kalman Kalman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline Hemoglobin, Platlets,White blood counts", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks,24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042482"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaplan Medical Center", 
            "investigator_full_name": "Dr Kalman Filanovsky", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "24 weeks,52 weeks"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "24 weeks 52 weeks"
            }, 
            {
                "measure": "Quality of life.", 
                "safety_issue": "No", 
                "time_frame": "12 weeks 24 weeks 36weeks"
            }
        ], 
        "source": "Kaplan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Weizmann Institute of Science", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Kaplan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}